Oppenheimer & Co’s Corcept Therapeutics CORT Stock Holding History

Oppenheimer & Co’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Hold	16,000	–	–	0.01%	788
2026 Q1	$645K	Hold	16,000	–	–	0.01%	1080
2025 Q4	$557K	Sell	16,000 -2,421	-13%	-$190K	0.01%	1034
2025 Q3	$1.53M	Hold	18,421	–	–	0.02%	705
2025 Q2	$1.35M	Sell	18,421 -3,825	-17%	-$277K	0.02%	724
2025 Q1	$2.54M	Buy	22,246 +6,246	+39%	+$380K	0.04%	479
2024 Q4	$806K	Sell	16,000 -8,774	-35%	-$460K	0.01%	887
2024 Q3	$1.15M	Buy	24,774 +4,774	+24%	+$170K	0.02%	743
2024 Q2	$650K	Hold	20,000	–	–	0.01%	917
2024 Q1	$504K	Hold	20,000	–	–	0.01%	984
2023 Q4	$650K	Hold	20,000	–	–	0.01%	876
2023 Q3	$545K	Hold	20,000	–	–	0.01%	907
2023 Q2	$445K	Hold	20,000	–	–	0.01%	1015
2023 Q1	$433K	Hold	20,000	–	–	0.01%	997
2022 Q4	$406K	Hold	20,000	–	–	0.01%	977
2022 Q3	$513K	Hold	20,000	–	–	0.01%	890
2022 Q2	$476K	Sell	20,000 -2,000	-9%	-$43.6K	0.01%	939
2022 Q1	$495K	Buy	+22,000	New	+$468K	0.01%	1006
2021 Q4	–	Sell	-20,000	Closed	-$394K	–	1499
2021 Q3	$394K	Hold	20,000	–	–	0.01%	1113
2021 Q2	$440K	Buy	+20,000	New	+$445K	0.01%	1089
2016 Q1	–	Sell	-20,000	Closed	-$100K	–	1257
2015 Q4	$100K	Hold	20,000	–	–	﹤0.01%	1207
2015 Q3	$75K	Buy	+20,000	New	+$101K	﹤0.01%	1288

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co's CORT Position: Q2 2026 in Review

Oppenheimer & Co held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 16,000 shares worth $1.39M. The position accounts for 0.01% of the portfolio, ranked #788.

Oppenheimer & Co first reported a position in CORT in Q3 2015 and has held it in 22 quarters since. The position peaked at $2.54M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Oppenheimer & Co held 16,000 shares of Corcept Therapeutics worth $1.39M as of Q2 2026.
Oppenheimer & Co left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #788 holding.
Oppenheimer & Co first reported a position in Corcept Therapeutics in Q3 2015 and has held it in 22 quarters since.
Oppenheimer & Co's Corcept Therapeutics position peaked at $2.54M in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.